Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Giessen
Clinical trial register · Germany

Clinical Trials in Giessen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2873
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Giessen16 Janssen Research & Development, LLC7 Merck Sharp & Dohme LLC6 Sanofi5 Hoffmann-La Roche4
Site location
Berlin1586 Hamburg889 Essen766 Dresden716 Heidelberg627
All 639 locations
Target enrolment
to

Trials with a site in Giessen

167 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Zoll Medical Corporation
Not applicable
800
Giessen
2026-10-01
Recruiting
CSL Behring
Phase 3
63
Giessen, Mainz
2026-09-15
Not yet open
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
Asklepios proresearch
Not applicable
264
Bad Oeynhausen, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Herne, Leipzig
2026-08-19
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bonn, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg
2026-06-11
Recruiting
Bayer
Phase 3
117
Tübingen, Giessen, Cologne
2026-06-01
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Giessen
2026-05-03
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Cologne, Essen, Giessen, Greifswald, Hamburg, Hanover, Munich
2026-04-23
Recruiting
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Heidelberg, Giessen
2026-02-02
Recruiting
Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures
NCT07488468Preoperative Fasting, Perioperative Patient Comfort / Quality of Care, Postoperative Nausea and Vomiting (PONV), Postoperative Pulmonary Complications
University of Giessen
Observational
1,000
Giessen
2026-01-30
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Löwenstein, Frankfurt am Main, Giessen, Cologne
2025-12-22
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Giessen
2025-12-17
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Bonn, Essen, Frankfurt, Giessen, Hanover, Leipzig, Regensburg, Rostock
2025-12-03
Recruiting
Bayer
Phase 3
111
Giessen, Cologne, Tübingen
2025-11-19
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
40
Aachen, Bonn, Essen, Frankfurt, Giessen, Göttingen, Hamburg, Jena
2025-11-18
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Active, closed
Pfizer
Phase 2
42
Heidelberg, Regensburg, Giessen, Greifswald, Dresden
2025-11-10
Recruiting
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Recruiting
Pfizer
Phase 3
680
Heidelberg, Stuttgart, Hösbach, Frankfurt am Main, Giessen, Immenhausen, Kassel, Bonn
2025-09-29
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
Giessen
2025-08-06
Recruiting
Reprieve Cardiovascular, Inc
Not applicable
400
Giessen, Hanover, Heidelberg
2025-07-28
Recruiting
Pfizer
Phase 3
714
Ulm, Gröbenzell, Traunstein, Giessen, Kassel, Koblenz, Chemnitz, Halle
2025-07-23
Recruiting
GlaxoSmithKline
Phase 3
961
Munich, Fürstenwalde, Darmstadt, Giessen, Offenbach, Rheine, Bendorf, Halle
2025-06-23
Active, closed
Biogen
Phase 3
255
Aachen, Giessen, Hamburg
2025-06-09
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
Giessen, München, Tübingen
2025-06-04
Recruiting
Sanofi
Observational
150
Aschaffenburg, Augsburg, Dachau, Erlangen, Giessen, Wetzlar, Osnabrück, Weyhe-Kirchweyhe
2025-05-28
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Recruiting
Brain Signal Training to Enhance Affect Down-regulation
NCT06626789Borderline Personality Disorder
Central Institute of Mental Health, Mannheim
Phase 1/2
164
Freiburg im Breisgau, Giessen, Halle, Hamburg, Mannheim, Tübingen
2025-04-23
Recruiting
University Hospital, Bonn
Phase 2
176
Freiburg im Breisgau, Stuttgart, Giessen, Minden, Bonn
2025-04-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cologne, Giessen
2025-03-18
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Giessen, Hanover, Jena, Tübingen
2025-02-10
Active, closed
Genmab
Phase 3
584
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Recruiting
Basilea Pharmaceutica
Phase 3
450
Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg
2024-12-11
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Giessen, Immenhausen, Hanover, Essen, Berlin, Leipzig
2024-11-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Regensburg, Dresden, Berlin, Giessen, Greifswald, Heidelberg, Homburg
2024-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Heidelberg, Stuttgart, Kempten (Allgäu), Giessen, Oldenburg, Eschweiler, Münster, Mainz
2024-10-21
Recruiting
Boehringer Ingelheim
Phase 2
588
Berlin, Giessen, Hamburg, Leipzig, Mannheim, München
2024-10-11
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum
2024-09-18
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Recruiting
University of Giessen
Not applicable
1,057
Giessen
2024-09-01
Recruiting
Bayer
Phase 3
444
Stuttgart, Nuremberg, Frankfurt am Main, Giessen, Cologne, Essen, Hemer, Berlin
2024-08-28
Active, closed
Viridian Therapeutics, Inc.
Phase 3
204
Berlin, Dresden, Giessen, Göttingen
2024-08-27
Active, closed
Viridian Therapeutics, Inc.
Phase 3
132
Berlin, Dresden, Giessen, Göttingen
2024-08-27
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart
2024-08-15
Recruiting
Hoffmann-La Roche
Phase 4
28
Berlin, Giessen
2024-08-14
Recruiting
Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension
NCT06291714Intraoperative Hypotension, Acute Kidney Injury, Myocardial Injury After Non-cardiac Surgery
University of Giessen
Not applicable
150
Giessen
2024-08-01
Recruiting
NovoCure GmbH
Phase 3
734
Berlin, Giessen, Halle, Heidelberg, Löwenstein, Oldenburg
2024-07-31
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Immenhausen, Essen, Großhansdorf, Esslingen am Neckar, Giessen, Hamburg, Hemer, Neuss
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Bad Homburg, Berlin, Bochum, Essen, Giessen, Tübingen
2024-07-12
Recruiting
University Hospital, Basel, Switzerland
Not applicable
498
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Giessen, Kiel
2024-07-04
Recruiting
AO Innovation Translation Center
Observational
600
Frankfurt, Giessen, Heidelberg, Münster, Wildeshausen
2024-07-03
Active, closed
Merus B.V.
Phase 3
621
Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München
2024-06-25
Active, closed
Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS)
NCT06723418Inflammatory Bowel Diseases (IBD), Crohns Disease, Ulcerative Colitis (UC)
University of Glasgow
Observational
2,000
Giessen
2024-06-15
Active, closed
Exelixis
Phase 2/3
600
Giessen
2024-06-07
Recruiting
Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension
NCT06409624Pulmonary Hypertension, Chronic Kidney Disease
University of Giessen
Observational
400
Bad Nauheim, Giessen
2024-05-31
Recruiting
Hoffmann-La Roche
Phase 4
28
Berlin, Giessen
2024-05-30
Recruiting
Daiichi Sankyo
Phase 3
540
Berlin, Erfurt, Essen, Frankfurt, Frankfurt am Main, Gauting, Gera, Giessen
2024-05-21
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Düsseldorf, Essen, Giessen, Hamburg
2024-04-16
Recruiting
Cohort Study on Plant-based Diets (COPLANT Study)
NCT06323538Dietary Exposure, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Bone Loss
German Federal Institute for Risk Assessment
Observational
6,000
Karlsruhe, Jena, Berlin, Bonn, Giessen, Heidelberg, Regensburg
2024-04-09
Recruiting
GlaxoSmithKline
Phase 3
864
Augsburg, Berlin, Erlangen, Essen, Giessen, Hamburg, Neuruppin, Straubing
2024-03-21
Recruiting
Medical University Innsbruck
Not applicable
1,350
Essen, Freiburg im Breisgau, Giessen, Jena
2024-03-12
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Aachen, Essen, Giessen, Heidelberg, Kassel, Kiel
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 1
46
Giessen
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Colorado Prevention Center
Phase 3
5,200
Lübeck, Berlin, Jena, Dresden, Giessen, Regensburg
2024-01-17
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg
2024-01-11
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Berlin, Giessen, Hamburg
2023-12-20
Recruiting
Nykode Therapeutics ASA
Phase 1/2
110
Giessen
2023-12-19
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Hamburg, Giessen, München, Regensburg
2023-12-18
Active, closed
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Böblingen, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Recruiting
University of Giessen
Not applicable
34
Giessen
2023-12-01
Recruiting
Giessen Stroke Registry
NCT05295862Stroke, Acute, Comorbidities and Coexisting Conditions, Critical Care
University of Giessen
Observational
2,000
Giessen
2023-11-30
Active, closed
argenx
Observational
413
Essen, Giessen, Hanover, Potsdam, Würzburg
2023-11-29
Active, closed
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Berlin, Giessen
2023-11-27
Active, closed
GlaxoSmithKline
Phase 2
316
Frankfurt am Main, Essen, Aachen, Berlin, Giessen, Hamburg, Regensburg, Ulm
2023-11-14
Active, closed
medac GmbH
Phase 2
49
Aachen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hanover, Jena, Leipzig
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Dresden, Jena, Giessen
2023-08-16
Recruiting
Dr. F. Köhler Chemie GmbH
Phase 2
15
Berlin, Giessen, München
2023-08-15
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Kassel, Dresden, Giessen, Regensburg
2023-07-31
Recruiting
Amicus Therapeutics
Phase 3
36
Giessen, Heidelberg, Höchheim, Münster
2023-07-18
Active, closed
Swedish Orphan Biovitrum
Observational
165
Goettigen, Aschaffenburg, Frankfurt am Main, Giessen, Offenbach, Essen, Leipzig, Saalfeld
2023-06-26
Recruiting
Universität des Saarlandes
Phase 3
330
Homburg, Aschaffenburg, Berlin, Dresden, Giessen, Greifswald, Halle, Karlsruhe
2023-06-07
Active, closed
Universität des Saarlandes
Phase 2
50
Ulm, Augsburg, Erlangen, Regensburg, Frankfurt am Main, Giessen, Düsseldorf, Homburg
2023-05-25
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
München, Frankfurt, Giessen, Halle, Kempten
2023-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
Heidelberg, Giessen, Hanover, Dresden, Lübeck
2023-03-16
Active, closed
AbbVie
Phase 3
520
Esslingen am Neckar, Heidelberg, Erlangen, Giessen, Bielefeld, Bonn, Dortmund, Mainz
2023-03-15
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Frankfurt am Main, Dresden, Jena, Essen, Giessen
2023-02-03
Active, closed
Daiichi Sankyo
Phase 3
1,170
Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich
2023-01-11
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Dresden, Essen, Giessen, Hanover
2022-12-30
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Augsburg, Berlin, Bonn, Dortmund, Dresden, Erlangen, Giessen, Halle
2022-12-15
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Berlin, Erlangen, Essen, Frankfurt, Giessen, Hanover, Jena, Mainz
2022-11-08
Active, closed
Genmab
Phase 3
549
Tübingen, Würzburg, Giessen, Kassel, Göttingen, Bonn, Dresden, Leipzig
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Berlin, Georgsmarienhütte, Giessen, Münster, Recklinghausen, Weinsberg
2022-08-05
Recruiting
Susanne Rogers
Not applicable
200
Bochum, Giessen, Kiel
2022-07-29
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,546
Mannheim, Tübingen, Munich, Nuremberg, Regensburg, Frankfurt am Main, Giessen, Buxtehude
2022-07-14
Active, closed
Daiichi Sankyo
Phase 3
586
Essen, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Großhansdorf, Heidelberg, Immenhausen
2022-07-08
Recruiting
IntraBio Inc
Phase 3
53
Giessen, Hamburg, Höchheim, München, Münster
2022-06-30
Active, closed
University of Giessen
Observational
200
Giessen
2022-04-15
Recruiting
AbbVie
Phase 3
768
Heidelberg, Mannheim, Gauting, Giessen, Kassel, Dresden, Bad Berka, Berlin
2022-03-25
Active, closed
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 3
86
Giessen, Hamburg, Höchheim, Mainz
2022-02-14
Active, closed
Asklepios proresearch
Not applicable
350
Bad Nauheim, Berlin, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Hamburg-Nord
2021-12-15
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Giessen, Hanover, Jena, München, Rostock
2021-12-10
Active, closed
University of Leipzig
Not applicable
262
Coburg, Giessen, Münster, Dresden, Berlin, Leipzig
2021-11-12
Active, closed
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
1,899
Erlangen, Giessen, Homburg, Leipzig, Lübeck
2021-10-20
Active, closed
Leipzig Heart Science gGmbH
Not applicable
836
Bad Berka, Bad Oeynhausen, Cologne, Dortmund, Giessen, Leipzig, München, Tübingen
2021-08-30
Active, closed
AstraZeneca
Phase 3
712
Bielefeld, Bochum, Cologne, Düsseldorf, Giessen, Hanover, Herne, Magdeburg
2021-08-05
Active, closed
Boehringer Ingelheim
Phase 1
554
Augsburg, Cologne, Dresden, Giessen, Oldenburg
2021-07-02
Active, closed
Sanofi
Observational
16
Giessen
2021-06-10
Recruiting
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
NCT05337631HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer
University Hospital Freiburg
Observational
1,500
Berlin, Erlangen, Frankfurt, Giessen, Halle, Jena, Kiel, Leipzig
2021-06-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Heidelberg, Munich, Regensburg, Giessen, Hanover, Cologne, Dresden, Leipzig
2021-05-12
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Berlin, Düsseldorf, Giessen, Hanover, Kiel, München, Münster, Regensburg
2021-04-24
Active, closed
Sarepta Therapeutics, Inc.
Observational
205
Giessen, Essen
2021-04-22
Active, closed
Incyte Corporation
Phase 3
654
Amberg, Berlin, Essen, Giessen, Greifswald, Landshut, Mainz, Mannheim
2021-04-15
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg
2021-04-08
Recruiting
COVID-19 Vaccines Safety Tracking (CoVaST)
NCT04834869Adverse Reaction to Vaccine, COVID19 Vaccine
DrugsComirnaty·Spikevax
Masaryk University
Observational
30,000
Giessen
2021-04-01
Active, closed
Hoffmann-La Roche
Phase 3
746
Berlin, Böblingen, Dresden, Giessen, Kiel, Stuttgart, Tübingen, Ulm
2021-03-17
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Bad Berka, Bonn, Cologne, Essen, Gauting, Giessen, Grohansdorf, Halle
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Frankfurt, Giessen, Regensburg
2021-02-23
Recruiting
Biosense Webster, Inc.
Observational
8,000
Bad Neustadt an der Saale, Bad Oeynhausen, Bad Segeberg, Bautzen, Essen, Frankfurt, Giessen, Hamburg
2021-02-22
Active, closed
Michael Hopp
Phase 2
105
Immenstadt im Allgäu, München Gauting, Potsdam, Giessen, Kassel, Offenbach, Rostock, Aachen
2020-12-21
Active, closed
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Elixir Medical Corporation
Not applicable
445
Bad Nauheim, Bad Segeberg, Coburg, Dortmund, Erlangen, Essen, Frankfurt, Giessen
2020-12-16
Recruiting
Alnylam Pharmaceuticals
Observational
1,500
Berlin, Giessen, Hanover
2020-11-23
Recruiting
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
NCT03497637Coronary Artery Disease, Coronary Artery Stenoses
Helios Health Institute GmbH
Not applicable
1,054
Dresden, Erlangen, Essen, Giessen, Leipzig, Ludwigshafen, Neuss
2020-10-23
Recruiting
University of Giessen
Observational
495
Ulm, Giessen
2020-10-01
Active, closed
Michael Hopp
Phase 4
34
München, Giessen, Offenbach, Berlin, Bremen, Hamburg, Hamm, Immenstadt im Allgäu
2020-09-11
Active, closed
Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT04444492Central Retinal Vein Occlusion With Macular Edema
DrugsLucentis·Ranibizumab
University of Giessen
Phase 3
88
Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster
2020-08-25
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Freiburg im Breisgau, Giessen, Jena
2020-07-10
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Berlin, Lübeck, Bad Segeberg, Bonn, Frankfurt, Giessen, Mainz, Munich
2020-07-07
Recruiting
Giessen Pulmonary Hypertension in Lung Cancer Registry
NCT04467333Pulmonary Hypertension Due to Lung Diseases and Hypoxia
University of Giessen
Observational
500
Giessen
2020-06-29
Recruiting
Sequelae of Sars-CoV-2 Infections
NCT04442789Lung Diseases, Cardiac Disease, Inflammatory Reaction
University of Giessen
Observational
120
Giessen
2020-05-20
Recruiting
PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension
NCT05329714Pulmonary Hypertension, Global Health
University of Giessen
Observational
40,000
Giessen
2020-01-30
Recruiting
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
DrugWarfarin
Population Health Research Institute
Phase 3
2,625
Giessen, Jena
2019-09-05
Active, closed
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
NCT04430075Mitral Regurgitation, Mitral Insufficiency
Edwards Lifesciences
Observational
1,000
Bad Krozingen, Tübingen, Ulm, Erlangen, München, Bernau bei Berlin, Giessen, Göttingen
2019-08-23
Active, closed
Tesaro, Inc.
Phase 3
785
Amberg, Bad Homburg, Cologne, Dessau, Dresden, Essen, Frankfurt, Giessen
2019-07-18
Active, closed
SIRONA 2 Trial Heart Failure NYHA Class III
NCT04012944Heart Failure NYHA Class III
Endotronix, Inc.
Not applicable
81
Cologne, Giessen, Hanover
2019-06-26
Recruiting
Insel Gruppe AG, University Hospital Bern
Not applicable
104
Giessen, Erlangen
2019-05-28
Active, closed
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
NCT03913143Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
DrugSepofarsen
ProQR Therapeutics
Phase 2/3
36
Giessen, Tübingen
2019-04-04
Recruiting
University Hospital, Essen
Not applicable
80
Essen, Giessen
2019-01-15
Recruiting
Pulmonary Hemodynamics During Exercise - Research Network
NCT03954574Pulmonary Circulation Diseases
Medical University of Graz
Observational
1,500
Cologne, Giessen, Greifswald, Heidelberg, Würzburg
2018-12-01
Active, closed
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Edwards Lifesciences
Not applicable
1,247
Bad Oeynhausen, Cologne, Dresden, Essen, Giessen, Hamburg, Heidelberg, Leipzig
2018-11-30
Active, closed
AbbVie
Phase 2
270
Mannheim, Augsburg, Giessen, Kassel, Oldenburg, Halle, Berlin, Gauting
2018-10-10
Recruiting
Charite University, Berlin, Germany
Observational
500
Berlin, Giessen, Hanover, Heidelberg
2018-07-01
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Leipzig, Bad Berka, Bad Oeynhausen, Berlin, Brandenburg, Buchholz, Erlangen, Giessen
2018-05-14
Active, closed
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Berlin, Dresden, Düsseldorf, Essen, Fürth, Giessen, Hamburg, Hanover
2018-05-03
By invitation
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
NCT03388476Hypertension, Pulmonary, Hypertension;Pulmonary;Primary, Chronic Thromboembolic Pulmonary Hypertension, Vascular Diseases
University of Giessen
Observational
500
Giessen
2018-05-02
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
Munich, Giessen, Essen, Münster, Berlin
2018-04-09
Recruiting
Randomization of Single vs Multiple Arterial Grafts
NCT03217006Coronary Artery Disease, Heart Diseases
Weill Medical College of Cornell University
Not applicable
4,300
Duisburg, Düsseldorf, Erlangen, Giessen, Göttingen, Jena, Leipzig, Oeynhausen
2018-01-07
Recruiting
University of Giessen
Observational
200
Giessen
2017-10-01
Active, closed
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
NCT03252938Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
DrugsEfti·Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1
83
Bad Saarow, Cologne, Essen, Frankfurt, Giessen, Hamburg, Herne, Mainz
2017-08-15
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Bad Nauheim, Dresden, Essen, Freiburg im Breisgau, Giessen, Hamburg
2016-03
Active, closed
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
DrugCisplatin
Lisette Nixon
Phase 3
1,269
Berlin, Giessen, Hamburg, Homburg, Leipzig, Potsdam, Solingen, Ulm
2015-10
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bad Reichenhall, Würzburg, Bochum, Düsseldorf, Dresden, Berlin, Cologne, Giessen
2015-01-20
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Berlin, Dresden, Essen, Giessen, Heidelberg, Homburg/Saar, Magdeburg, Marburg
2013-09-09
Recruiting
St. Anna Kinderkrebsforschung
Phase 2/3
1,800
Giessen, Aachen, Berlin, Bonn, Düsseldorf, Erlangen, Essen, Frankfurt am Main
2013-04
Recruiting
Heidelberg University
Observational
200
Heidelberg, Giessen, Hanover, Lübeck
2011-12
Active, closed
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
NCT02951416Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases
Andreas Guenther
Observational
2,000
Giessen, Greifenstein
2009-09
Recruiting
COMPERA / COMPERA-KIDS
NCT01347216Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
Technische Universität Dresden
Observational
14,000
Berlin, Giessen, Hanover, Munich
2007-07-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Berlin, Bochum, Bonn, Freiburg im Breisgau, Giessen, Halle, Hamburg, Mainz
2004-09-15
Recruiting
University of Giessen
Observational
6,300
Giessen
2004-09-01
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Berlin, Giessen, Münster, Würzburg
2001-07-31
Recruiting
Giessen Pulmonary Hypertension Registry and Biobank
NCT04145024Pulmonary Hypertension
University of Giessen
Observational
10,000
Giessen
1993-07
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Berlin, Düsseldorf, Giessen, Hamburg, Mainz, Oberhausen
1991-04-01
Rows per page Showing 1–167 of 167
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/giessen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 167 of those studies with a site in Giessen.

How many clinical trials are recruiting in Giessen?

86 of the 167 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 2 have not yet opened recruitment, 77 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Giessen), 167 studies
PhaseStudiesRecruitingShare
Phase 3653038.9%
Observational392723.4%
Not applicable241414.4%
Phase 224814.4%
Phase 1402.4%
Phase 1/2442.4%
Phase 4422.4%
Phase 2/3311.8%

Most active sponsors

Lead sponsors with the most studies (Giessen)
Lead sponsorStudiesRecruiting
University of Giessen1613
Janssen Research & Development, LLC74
Merck Sharp & Dohme LLC62
Sanofi51
Boehringer Ingelheim41
GlaxoSmithKline42
Hoffmann-La Roche42
Novartis Pharmaceuticals41
Regeneron Pharmaceuticals40
AbbVie31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.